Bryophyllum Pinnatum Tea as a Novel Treatment for Recurrent Kidney Stone Formers
Launched by INDRA GUPTA · May 15, 2025
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Background and Rationale:
Kidney stones are hard deposits that consist of calcium complexed with phosphate or oxalate, thus, high urinary calcium content is a major risk factor. The precipitation of calcium can arise from various mechanisms including the aggregation of urinary calcium crystals from impaired transport along the nephron, reduced urinary inhibitors (e.g. citrate), and increased oxidative stress and inflammation. Large stones can block the drainage system of the kidney, causing acute severe pain and inflammation. Recurrent kidney stones can lead to sustained inflammation resul...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-70 years of age at time of study enrollment
- • 1 calcium-based stone event within a 3-year interval and/or hypercalciuria on a 24h urine collection (\>5 mmol/day)
- • They had an ultrasound or CT imaging within the previous 6 months which showed no evidence of current obstructive kidney stone
- • Adhering to the stone prevention diet (high water/low salt/low protein intake) for at least one month prior to enrollment in study but not taking any stone-preventing medications
- • Agrees to maintain current lifestyle habits and avoid taking new supplements during the study period
- Exclusion Criteria:
- • Patients with secondary causes for calcium stone formation (primary hyperparathyroidism, inflammatory bowel disease, hyperuricosuria, and cancer)
- • Patients who are pregnant or nursing or who are trying to become pregnant
- • Currently consuming B. pinnatum or any natural health product containing polyphenols
- • A known intolerance or allergy to the plant B. pinnatum
- • Currently taking stone-preventing medication
- • Gluten intolerance or allergy
About Indra Gupta
Indra Gupta is a dedicated clinical trial sponsor with a focus on advancing medical research and improving patient outcomes through innovative trial design and execution. With a strong background in clinical operations and regulatory compliance, Indra is committed to fostering collaboration among stakeholders, including research institutions, healthcare professionals, and patient advocacy groups. By prioritizing transparency and ethical standards, Indra Gupta aims to accelerate the development of groundbreaking therapies and contribute to the overall enhancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Indra Gupta, MD
Principal Investigator
Research Institute at the McGill University Health Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported